权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

AROMATASE INHIBITORS: SKELETAL EFFECTS AND THE ROLE OF CYP19 GENE POLYMORPHISMS

芳香酶抑制剂：骨骼效应和 CYP19 基因多态性的作用

基本信息

批准号：
7267973
负责人：
REINA C VILLAREAL
金额：
$ 16.24万
依托单位：
WASHINGTON UNIVERSITY
依托单位国家：
美国
项目类别：
财政年份：
2006
资助国家：
美国
起止时间：
2006-07-01 至 2009-06-30
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/7267973
关键词：
Acute Address Adjuvant Therapy Adrenal Glands Adverse effects Age-Related Bone Loss Alleles Anabolism Androgens Androstenedione Aromatase Aromatase Inhibition Aromatase Inhibitors Bone Density Breast Cancer Prevention CYP19A1 gene Chronic Class Coagulation Process Code Conflict (Psychology)Data Development Diagnosis Disease Disease-Free Survival Endometrial Carcinoma Enzyme Inhibitor Drugs Enzyme Inhibitors Enzymes Estradiol Estrogen receptor negative Estrogen receptor positive Estrogens Estrone Ethnic group Exemestane Exhibits Failure Fracture Generations Genes Genetic Polymorphism Genetic Variation Genotype Goals Hand High Prevalence Incidence Lead Letrozole Longitudinal Studies Marketing Measurement Menopause Neck Normal tissue morphology Numbers Osteoporosis Ovarian Ovariectomy Pathway interactions Patients Pharmaceutical Preparations Pilot Projects Postmenopause Predisposition Production Rate Rattus Reporting Research Research Personnel Risk Role Route Serum Skeletal system Source Staging System Tamoxifen Testing Thromboembolism Time Total Estrogen Blockade Uterus Variant Woman anastrozole base bone health bone loss bone metabolism bone turnover clinically significant design enzyme activity experience follow-up hormone therapy improved malignant breast neoplasm prevent programs response sex trend

项目摘要

DESCRIPTION (provided by applicant): The use of tamoxifen as the first line agent for endocrine therapy of estrogen receptor positive (ER+) breast cancer has recently been challenged by a newer class drugs, the aromatase inhibitors, which are found to have superior efficacy over tamoxifen with better side-effect profile. On the other hand, because of it's mechanism of action, bone loss is understandably a concern among these women. Reports of an increased incidence of fractures in women on aromatase inhibitors, a few were significant and some not, came from studies that were not designed to investigate the skeletal effects of the drug. No data on bone mineral density (BMD) were available from these studies, thus, bone loss was not adequately addressed. Previous studies have identified certain polymorhisms of the CYP19 gene (the gene that codes for the aromatase enzyme) to be associated with differences in enzymatic activity and BMD. Whether these polymorphisms influence the skeletal response to aromatase inhibition remains undetermined. We hypothesize that the use of aromatase inhibitors is associated with significant bone loss, and the degree of bone loss will be determined by polymorphisms of the CYP19 gene. To test this hypothesis we propose to do a one-year longitudinal study of postmenopausal women from different ethnic groups who will be initiated on aromatase inhibitors for breast cancer. Women with breast cancer but will not be put on aromatase inhibitors will serve as controls. We will obtain BMD measurements and markers bone turnover at baseline and on follow-up. We will also genotype these women for CYP19 gene polymorphisms associated with differences BMD. We will compare the rates of bone loss in women on aromatase inhibitors versus those not taking the drug, and also among the different variants of the different polymorphisms examined. We anticipate that significant bone loss is associated with aromatase inhibitor therapy and but certain variants of the CYP19 gene are especially more sensitive to inhibition, thus, will be experiencing more bone loss than others. The data generated from this proposed study will be used to develop a full-scale proposal with the goal of establishing the appropriate approach to maintaining bone health in women given aromatase inhibitors. As more patients are surviving breast cancer, more will be expected to experience osteoporotic complications from endocrine therapies intended to improve survival, thus, this issue needs to be addressed.

描述（由申请人提供）：他莫昔芬作为雌激素受体阳性（ER+）乳腺癌内分泌治疗的一线药物的使用最近受到了一类新药物芳香酶抑制剂的挑战，发现芳香酶抑制剂具有比他莫昔芬更好的上级疗效和更好的副作用。另一方面，由于它的作用机制，骨质流失是这些妇女中可以理解的一个问题。关于服用芳香酶抑制剂的女性骨折发生率增加的报道，有些是显著的，有些不是，来自于那些不是为了研究药物对骨骼影响的研究。这些研究中未获得骨矿物质密度（BMD）数据，因此未充分解决骨丢失问题。先前的研究已经确定了CYP19基因（编码芳香酶的基因）的某些多态性与酶活性和BMD的差异相关。这些多态性是否影响骨骼对芳香化酶抑制的反应仍不确定。我们假设芳香化酶抑制剂的使用与显著的骨丢失相关，并且骨丢失的程度将由CYP 19基因的多态性决定。为了验证这一假设，我们建议对不同种族的绝经后妇女进行为期一年的纵向研究，这些妇女将开始使用芳香酶抑制剂治疗乳腺癌。患有乳腺癌但不服用芳香化酶抑制剂的妇女将作为对照。我们将在基线和随访时获得BMD测量值和骨转换标志物。我们还将对这些妇女进行与BMD差异相关的CYP19基因多态性的基因分型。我们将比较服用芳香化酶抑制剂与未服用该药物的妇女的骨丢失率，以及所检查的不同多态性的不同变体之间的骨丢失率。我们预计，显着的骨丢失与芳香化酶抑制剂治疗有关，但CYP19基因的某些变体对抑制特别敏感，因此，将经历比其他人更多的骨丢失。从这项拟议的研究中产生的数据将用于制定一个全面的建议，其目标是建立适当的方法来维持给予芳香酶抑制剂的妇女的骨骼健康。随着越来越多的乳腺癌患者幸存下来，预计将有更多的人因旨在提高生存率的内分泌治疗而出现乳腺癌并发症，因此，需要解决这个问题。